董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Glazek | 男 | Director | 40 | 未披露 | 未持股 | 2018-03-12 |
| Thomas F. Helms, Jr. | 男 | Director | 77 | 5.33万美元 | 未持股 | 2018-03-12 |
| Gregory H. A Baxter | 男 | Executive Chairman and Secretary | 64 | 1.25万美元 | 未持股 | 2018-03-12 |
| Ian Estus | 男 | President Chief Executive Officer and Director | 43 | 0.75万美元 | 未持股 | 2018-03-12 |
| David M. Wurzer | 男 | Director | 59 | 6.75万美元 | 未持股 | 2018-03-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gregory H. A Baxter | 男 | Executive Chairman and Secretary | 64 | 1.25万美元 | 未持股 | 2018-03-12 |
| Ian Estus | 男 | President Chief Executive Officer and Director | 43 | 0.75万美元 | 未持股 | 2018-03-12 |
| Edward J. Sweeney | 男 | Interim Chief Financial Officer | 48 | 未披露 | 未持股 | 2018-03-12 |
| Bradford A. Tobin | 男 | Secretary and General Counsel | 36 | 未披露 | 未持股 | 2018-03-12 |
董事简历
中英对照 | 中文 | 英文- David Glazek
-
David Glazek，他于2014年8月2日被任命为董事，并作为薪酬和提名和治理委员会的成员。他于2008年加入Standard General公司，并一直担任合伙人（2012年以来）。他目前担任North Atlantic Holding Company的董事、Standard Carbon公司的经理、Upstate Power Producers公司的董事会监察员。加入Standard General公司之前，他曾担任Lazard Freres & Co.的投资银行职务，在那里他专注于并购和企业重组。他也曾任职于Blackstone Group公司。他持有Columbia Law School的法学博士学位，以及the University of Michigan的学士学位。
David Glazek has served as a director of our company since November 2012 and as Chairman of the Board since 2019. Mr. Glazek is a Partner and Portfolio Manager of Standard General L.P. “Standard General” and has been with Standard General since 2008. He was formerly an investment banker at Lazard Frères & Co. from 2000 to 2003 and from 2006 to 2008. Mr. Glazek holds a Bachelor of Arts from the University of Michigan and a J.D. from Columbia Law School. Mr. Glazek currently serves as a director of National Cinemedia, Inc. (NYSE: NCMI) and is an Adjunct Assistant Professor at Columbia Business School. - David Glazek，他于2014年8月2日被任命为董事，并作为薪酬和提名和治理委员会的成员。他于2008年加入Standard General公司，并一直担任合伙人（2012年以来）。他目前担任North Atlantic Holding Company的董事、Standard Carbon公司的经理、Upstate Power Producers公司的董事会监察员。加入Standard General公司之前，他曾担任Lazard Freres & Co.的投资银行职务，在那里他专注于并购和企业重组。他也曾任职于Blackstone Group公司。他持有Columbia Law School的法学博士学位，以及the University of Michigan的学士学位。
- David Glazek has served as a director of our company since November 2012 and as Chairman of the Board since 2019. Mr. Glazek is a Partner and Portfolio Manager of Standard General L.P. “Standard General” and has been with Standard General since 2008. He was formerly an investment banker at Lazard Frères & Co. from 2000 to 2003 and from 2006 to 2008. Mr. Glazek holds a Bachelor of Arts from the University of Michigan and a J.D. from Columbia Law School. Mr. Glazek currently serves as a director of National Cinemedia, Inc. (NYSE: NCMI) and is an Adjunct Assistant Professor at Columbia Business School.
- Thomas F. Helms, Jr.
-
Thomas F. Helms, Jr.，目前担任我们的执行主席（2006年5月以来）。此前，他曾担任董事会的非执行主席（从1997年6月到2006年5月）。他也曾担任我们的总裁。他于1988年创立我们的前身公司，从事收购Lorillard公司的某些松叶咀嚼烟草资产。他曾担任Culbro Corporation的无烟烟草部门的总裁兼首席执行官（始于1983年），直到1986年3月出售给American Maize-Products Company。从1979年到1982年，他曾担任Revlon公司的Etherea化妆品和名牌香水的总经理。从1964年到1979年，他曾担任Revlon公司的多种部门的营销和销售职务。
Thomas F. Helms, Jr. joined the Company as a director in August 2017. He has been a director of Turning Point since 1997 and has served as its Non-Executive Chairman since May 2016. He served as Executive Chairman from May 2006 to May 2016 and as Non-Executive Chairman from June 1997 to May 2006. He also formerly served as Turning Point’s President. Mr. Helms also formed the predecessor company of Turning Point to acquire certain loose leaf chewing tobacco assets of Lorillard, Inc. - Thomas F. Helms, Jr.，目前担任我们的执行主席（2006年5月以来）。此前，他曾担任董事会的非执行主席（从1997年6月到2006年5月）。他也曾担任我们的总裁。他于1988年创立我们的前身公司，从事收购Lorillard公司的某些松叶咀嚼烟草资产。他曾担任Culbro Corporation的无烟烟草部门的总裁兼首席执行官（始于1983年），直到1986年3月出售给American Maize-Products Company。从1979年到1982年，他曾担任Revlon公司的Etherea化妆品和名牌香水的总经理。从1964年到1979年，他曾担任Revlon公司的多种部门的营销和销售职务。
- Thomas F. Helms, Jr. joined the Company as a director in August 2017. He has been a director of Turning Point since 1997 and has served as its Non-Executive Chairman since May 2016. He served as Executive Chairman from May 2006 to May 2016 and as Non-Executive Chairman from June 1997 to May 2006. He also formerly served as Turning Point’s President. Mr. Helms also formed the predecessor company of Turning Point to acquire certain loose leaf chewing tobacco assets of Lorillard, Inc.
- Gregory H. A Baxter
-
GregoryH.A Baxter于2015年10月加入公司担任董事，并于2017年6月成为我们的执行主席。Baxter先生自2005年以来一直是一名独立的公司财务顾问，主要为中间市场公司和密切持有的业务。此前，从2003年到2005年，他曾担任Diaz&Altschul Capital Management公司的董事总经理兼对冲基金销售与市场营销主管，在那里他的主要工作重点是将其投资产品带给潜在的公司和机构客户。他也曾是投资委员会成员。加入Diaz&Altschul公司之前，他曾担任SG Cowen Securities Corporation（法国银行的美国投资银行，SOCI T G N RALE）的董事总经理兼通才/跨国并购主管（从2000年到2002年）。在那里，他重新建立了跨境努力，并在全球范围内从事食品、零售、消费品、运输和石油天然气等行业。他也曾担任SG Cowen公平意见审查委员会的成员。任职SG Cowen公司之前，他曾任职Rothschild公司近6年（从1994年到2000年），在那里他专注于为工业/工程公司提供建议，包括汽车、国内和跨国并购、收购和资产剥离。他也曾担任SW Capital公司（并购精品店，专门从事财富500强公司的中间市场交易）的创始成员。在此之前，他是欧文信托公司企业财务咨询部的Vice President，为银行的客户提供并购和其他企业财务建议。他是Turning PointBrands，Inc.的董事纽约证券交易所代码:TPB（“转折点”），其他烟草产品的领先提供商。Baxter先生拥有加拿大维多利亚大学（University of Victoria）的工商管理学士学位和伦敦艾维商学院（Ivey Business School）的工商管理硕士学位。
Gregory H. A Baxter joined the Company as a director in October 2015 and became our Executive Chairman in June 2017. Mr. Baxter has been an independent corporate finance consultant primarily for middle-market corporations and closely held businesses since 2005. Previously from 2003 to 2005 he was Managing Director and Head, Hedge Fund Sales and Marketing at Diaz & Altschul Capital Management, where his primary focus was bringing its investment products to prospective corporate and institutional clients. He was also a member of the Investment Committee. Immediately prior to joining Diaz & Altschul, he was Managing Director and Head of Generalist/Cross-Border Mergers & Acquisitions at SG Cowen Securities Corporation, the U.S. investment bank of French bank, Société Générale from 2000 to 2002. There, he re-established the cross-border effort and worked globally in industries such as food, retail, consumer products, transportation and oil and gas. He was also a member of the SG Cowen Fairness Opinion Review Committee. Prior to SG Cowen he was at Rothschild Inc. for almost six years, from 1994 to 2000 where he specialized in advising on industrial/engineering companies, including automotive, domestic and cross border mergers, acquisitions and divestitures. He was also a founding member of SW Capital, an M&A boutique that specialized in middle-market transactions for Fortune 500 companies. Prior to that, he was a Vice President of Irving Trust Company's Corporate Financial Counseling Department, providing M&A and other corporate finance advice to the bank's clients. He sits on the board of Turning Point Brands, Inc. NYSE: TPB ("Turning Point"), a leading provider of Other Tobacco Products. Mr. Baxter holds a holds a B.A. from the University of Victoria in Canada and an M.B.A. from the Ivey Business School in London. - GregoryH.A Baxter于2015年10月加入公司担任董事，并于2017年6月成为我们的执行主席。Baxter先生自2005年以来一直是一名独立的公司财务顾问，主要为中间市场公司和密切持有的业务。此前，从2003年到2005年，他曾担任Diaz&Altschul Capital Management公司的董事总经理兼对冲基金销售与市场营销主管，在那里他的主要工作重点是将其投资产品带给潜在的公司和机构客户。他也曾是投资委员会成员。加入Diaz&Altschul公司之前，他曾担任SG Cowen Securities Corporation（法国银行的美国投资银行，SOCI T G N RALE）的董事总经理兼通才/跨国并购主管（从2000年到2002年）。在那里，他重新建立了跨境努力，并在全球范围内从事食品、零售、消费品、运输和石油天然气等行业。他也曾担任SG Cowen公平意见审查委员会的成员。任职SG Cowen公司之前，他曾任职Rothschild公司近6年（从1994年到2000年），在那里他专注于为工业/工程公司提供建议，包括汽车、国内和跨国并购、收购和资产剥离。他也曾担任SW Capital公司（并购精品店，专门从事财富500强公司的中间市场交易）的创始成员。在此之前，他是欧文信托公司企业财务咨询部的Vice President，为银行的客户提供并购和其他企业财务建议。他是Turning PointBrands，Inc.的董事纽约证券交易所代码:TPB（“转折点”），其他烟草产品的领先提供商。Baxter先生拥有加拿大维多利亚大学（University of Victoria）的工商管理学士学位和伦敦艾维商学院（Ivey Business School）的工商管理硕士学位。
- Gregory H. A Baxter joined the Company as a director in October 2015 and became our Executive Chairman in June 2017. Mr. Baxter has been an independent corporate finance consultant primarily for middle-market corporations and closely held businesses since 2005. Previously from 2003 to 2005 he was Managing Director and Head, Hedge Fund Sales and Marketing at Diaz & Altschul Capital Management, where his primary focus was bringing its investment products to prospective corporate and institutional clients. He was also a member of the Investment Committee. Immediately prior to joining Diaz & Altschul, he was Managing Director and Head of Generalist/Cross-Border Mergers & Acquisitions at SG Cowen Securities Corporation, the U.S. investment bank of French bank, Société Générale from 2000 to 2002. There, he re-established the cross-border effort and worked globally in industries such as food, retail, consumer products, transportation and oil and gas. He was also a member of the SG Cowen Fairness Opinion Review Committee. Prior to SG Cowen he was at Rothschild Inc. for almost six years, from 1994 to 2000 where he specialized in advising on industrial/engineering companies, including automotive, domestic and cross border mergers, acquisitions and divestitures. He was also a founding member of SW Capital, an M&A boutique that specialized in middle-market transactions for Fortune 500 companies. Prior to that, he was a Vice President of Irving Trust Company's Corporate Financial Counseling Department, providing M&A and other corporate finance advice to the bank's clients. He sits on the board of Turning Point Brands, Inc. NYSE: TPB ("Turning Point"), a leading provider of Other Tobacco Products. Mr. Baxter holds a holds a B.A. from the University of Victoria in Canada and an M.B.A. from the Ivey Business School in London.
- Ian Estus
-
Ian Estus于2016年8月加入公司担任董事，并于2017年6月成为公司总裁兼首席执行官。2014年5月至2016年7月，Estus先生担任HC2控股公司投资董事总经理纽交所股票代码:HCHC，一家多元化控股公司，投资于包括制造业、海洋服务、保险、公用事业、电信和生命科学在内的多个行业。在加入HC2之前，Estus先生是哈宾格投资集团有限公司子公司Five Island Asset Management的高级副总裁。NYSE:HRG，2013年4月至2014年5月。加入Five Island之前，他曾任职Harbinger Capital Partners LLC11年，在那里他曾担任多种职务，在那里他曾担任交易员，并协助管理投资组合。在2002年加入Harbinger Capital之前，Estus先生是Smith Barney Asset Management高收益投资集团的交易助理。在担任该职位之前，Estus先生曾担任Smith Barney Asset Management共同基金会计集团的基金会计。
Ian Estus joined the Company as a director in August 2016 and became our President and Chief Executive Officer in June 2017. From May 2014 until July 2016 Mr. Estus was the Managing Director of Investments of HC2 Holdings, Inc. NYSE: HCHC, a diversified holding company with investments in various industries including manufacturing, marine services, insurance, utilities, telecommunications and life sciences. Prior to joining HC2 Mr. Estus was a Senior Vice President at Five Island Asset Management, a subsidiary of HRG Group, Inc. NYSE: HRG, from April 2013 to May 2014. Prior to joining Five Island, Mr. Estus spent eleven years at Harbinger Capital Partners LLC, where he served in various capacities as a trader and assisting in management of the portfolio. Prior to joining Harbinger Capital in 2002 Mr. Estus was a Trading Assistant in the Smith Barney Asset Management High Yield Investments Group. Prior to that role, Mr. Estus served as a Fund Accountant in the Mutual Fund Accounting Group of Smith Barney Asset Management. - Ian Estus于2016年8月加入公司担任董事，并于2017年6月成为公司总裁兼首席执行官。2014年5月至2016年7月，Estus先生担任HC2控股公司投资董事总经理纽交所股票代码:HCHC，一家多元化控股公司，投资于包括制造业、海洋服务、保险、公用事业、电信和生命科学在内的多个行业。在加入HC2之前，Estus先生是哈宾格投资集团有限公司子公司Five Island Asset Management的高级副总裁。NYSE:HRG，2013年4月至2014年5月。加入Five Island之前，他曾任职Harbinger Capital Partners LLC11年，在那里他曾担任多种职务，在那里他曾担任交易员，并协助管理投资组合。在2002年加入Harbinger Capital之前，Estus先生是Smith Barney Asset Management高收益投资集团的交易助理。在担任该职位之前，Estus先生曾担任Smith Barney Asset Management共同基金会计集团的基金会计。
- Ian Estus joined the Company as a director in August 2016 and became our President and Chief Executive Officer in June 2017. From May 2014 until July 2016 Mr. Estus was the Managing Director of Investments of HC2 Holdings, Inc. NYSE: HCHC, a diversified holding company with investments in various industries including manufacturing, marine services, insurance, utilities, telecommunications and life sciences. Prior to joining HC2 Mr. Estus was a Senior Vice President at Five Island Asset Management, a subsidiary of HRG Group, Inc. NYSE: HRG, from April 2013 to May 2014. Prior to joining Five Island, Mr. Estus spent eleven years at Harbinger Capital Partners LLC, where he served in various capacities as a trader and assisting in management of the portfolio. Prior to joining Harbinger Capital in 2002 Mr. Estus was a Trading Assistant in the Smith Barney Asset Management High Yield Investments Group. Prior to that role, Mr. Estus served as a Fund Accountant in the Mutual Fund Accounting Group of Smith Barney Asset Management.
- David M. Wurzer
-
David M. Wurzer，注册会计师，曾任我公司审计委员会主席，现在是我公司薪酬委员会委员，他于2010年7月29日被选为董事会董事。自2009年11月起他在被称为是康乃狄克州风险投资臂膀的Connecticut Innovations任投资常务董事。从1997年9月到2007年12月，他任CuraGen公司执行副总裁、财务主管及首席财务官，该公司是一家上市生物制药公司，主要从事开发治疗肿瘤的蛋白质、抗体及小分子治疗法。在他受雇于CuraGen公司之前，从1991年到1997年，他担任Value Health公司管理职务和高管职务，该公司主要从事业务协同、成本节约以及合并和收购业务，从1994年2月到1997年9月他担任的职务包括高级副总裁、财务主管和首席财务官。此外，从1980年到1991年，Wurzer先生担任Coopers & Lybrand公司及其继任公司管理和会计职务，其继任公司被普华永道会计事务所收购。Wurzer先生拥有圣母大学会计学学士学位。他现在是两家上市公司Strategic Diagnostics公司和Response Genetics公司以及5家私人生命科学和医疗保健公司董事，包括Axerion Therapeutics公司、CyVek公司、Post-N-Track公司、NovaTract Surgical公司和Thetis Pharmaceuticals公司。自2008年起，Wurzer先生定期提供咨询服务，相关的服务包括融资、分析降低成本相关的成本以及实施业务生产力策略。
David M. Wurzer joined the Company as a director in February 2010. Since 2009 Mr. Wurzer has served as Managing Director, Investments, Senior Managing Director, Investments, and beginning April 2014 as Executive Vice President and Chief Investment Officer at Connecticut Innovations CI, the State’s “venture capital arm.” He is responsible for oversight of the CI Ventures' venture capital portfolio and team, as well as sourcing and analyzing investment opportunities, leading CI investments in entrepreneurial high-tech ventures and advising portfolio companies. Prior to joining CI, Mr. Wurzer most recently served as Executive Vice President, Treasurer and Chief Financial Officer of CuraGen Corporation, a biopharmaceutical development company, from September 1997 through December 2007. He has over 30 years of financial experience with growth-oriented companies, including direct involvement with raising capital, strategic transactions and mergers and acquisitions, for both start-up companies and publicly-held entities. Mr. Wurzer serves on the boards of Thetis Pharmaceuticals, LLC and ReNetX Bio, Inc, which are privately held, and on the board of Summit Therapeutics plc (NASDAQ: SMMT, LON:SUMM), a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Mr. Wurzer holds a BBA degree in Accountancy from the University of Notre Dame. - David M. Wurzer，注册会计师，曾任我公司审计委员会主席，现在是我公司薪酬委员会委员，他于2010年7月29日被选为董事会董事。自2009年11月起他在被称为是康乃狄克州风险投资臂膀的Connecticut Innovations任投资常务董事。从1997年9月到2007年12月，他任CuraGen公司执行副总裁、财务主管及首席财务官，该公司是一家上市生物制药公司，主要从事开发治疗肿瘤的蛋白质、抗体及小分子治疗法。在他受雇于CuraGen公司之前，从1991年到1997年，他担任Value Health公司管理职务和高管职务，该公司主要从事业务协同、成本节约以及合并和收购业务，从1994年2月到1997年9月他担任的职务包括高级副总裁、财务主管和首席财务官。此外，从1980年到1991年，Wurzer先生担任Coopers & Lybrand公司及其继任公司管理和会计职务，其继任公司被普华永道会计事务所收购。Wurzer先生拥有圣母大学会计学学士学位。他现在是两家上市公司Strategic Diagnostics公司和Response Genetics公司以及5家私人生命科学和医疗保健公司董事，包括Axerion Therapeutics公司、CyVek公司、Post-N-Track公司、NovaTract Surgical公司和Thetis Pharmaceuticals公司。自2008年起，Wurzer先生定期提供咨询服务，相关的服务包括融资、分析降低成本相关的成本以及实施业务生产力策略。
- David M. Wurzer joined the Company as a director in February 2010. Since 2009 Mr. Wurzer has served as Managing Director, Investments, Senior Managing Director, Investments, and beginning April 2014 as Executive Vice President and Chief Investment Officer at Connecticut Innovations CI, the State’s “venture capital arm.” He is responsible for oversight of the CI Ventures' venture capital portfolio and team, as well as sourcing and analyzing investment opportunities, leading CI investments in entrepreneurial high-tech ventures and advising portfolio companies. Prior to joining CI, Mr. Wurzer most recently served as Executive Vice President, Treasurer and Chief Financial Officer of CuraGen Corporation, a biopharmaceutical development company, from September 1997 through December 2007. He has over 30 years of financial experience with growth-oriented companies, including direct involvement with raising capital, strategic transactions and mergers and acquisitions, for both start-up companies and publicly-held entities. Mr. Wurzer serves on the boards of Thetis Pharmaceuticals, LLC and ReNetX Bio, Inc, which are privately held, and on the board of Summit Therapeutics plc (NASDAQ: SMMT, LON:SUMM), a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Mr. Wurzer holds a BBA degree in Accountancy from the University of Notre Dame.
高管简历
中英对照 | 中文 | 英文- Gregory H. A Baxter
GregoryH.A Baxter于2015年10月加入公司担任董事，并于2017年6月成为我们的执行主席。Baxter先生自2005年以来一直是一名独立的公司财务顾问，主要为中间市场公司和密切持有的业务。此前，从2003年到2005年，他曾担任Diaz&Altschul Capital Management公司的董事总经理兼对冲基金销售与市场营销主管，在那里他的主要工作重点是将其投资产品带给潜在的公司和机构客户。他也曾是投资委员会成员。加入Diaz&Altschul公司之前，他曾担任SG Cowen Securities Corporation（法国银行的美国投资银行，SOCI T G N RALE）的董事总经理兼通才/跨国并购主管（从2000年到2002年）。在那里，他重新建立了跨境努力，并在全球范围内从事食品、零售、消费品、运输和石油天然气等行业。他也曾担任SG Cowen公平意见审查委员会的成员。任职SG Cowen公司之前，他曾任职Rothschild公司近6年（从1994年到2000年），在那里他专注于为工业/工程公司提供建议，包括汽车、国内和跨国并购、收购和资产剥离。他也曾担任SW Capital公司（并购精品店，专门从事财富500强公司的中间市场交易）的创始成员。在此之前，他是欧文信托公司企业财务咨询部的Vice President，为银行的客户提供并购和其他企业财务建议。他是Turning PointBrands，Inc.的董事纽约证券交易所代码:TPB（“转折点”），其他烟草产品的领先提供商。Baxter先生拥有加拿大维多利亚大学（University of Victoria）的工商管理学士学位和伦敦艾维商学院（Ivey Business School）的工商管理硕士学位。
Gregory H. A Baxter joined the Company as a director in October 2015 and became our Executive Chairman in June 2017. Mr. Baxter has been an independent corporate finance consultant primarily for middle-market corporations and closely held businesses since 2005. Previously from 2003 to 2005 he was Managing Director and Head, Hedge Fund Sales and Marketing at Diaz & Altschul Capital Management, where his primary focus was bringing its investment products to prospective corporate and institutional clients. He was also a member of the Investment Committee. Immediately prior to joining Diaz & Altschul, he was Managing Director and Head of Generalist/Cross-Border Mergers & Acquisitions at SG Cowen Securities Corporation, the U.S. investment bank of French bank, Société Générale from 2000 to 2002. There, he re-established the cross-border effort and worked globally in industries such as food, retail, consumer products, transportation and oil and gas. He was also a member of the SG Cowen Fairness Opinion Review Committee. Prior to SG Cowen he was at Rothschild Inc. for almost six years, from 1994 to 2000 where he specialized in advising on industrial/engineering companies, including automotive, domestic and cross border mergers, acquisitions and divestitures. He was also a founding member of SW Capital, an M&A boutique that specialized in middle-market transactions for Fortune 500 companies. Prior to that, he was a Vice President of Irving Trust Company's Corporate Financial Counseling Department, providing M&A and other corporate finance advice to the bank's clients. He sits on the board of Turning Point Brands, Inc. NYSE: TPB ("Turning Point"), a leading provider of Other Tobacco Products. Mr. Baxter holds a holds a B.A. from the University of Victoria in Canada and an M.B.A. from the Ivey Business School in London.- GregoryH.A Baxter于2015年10月加入公司担任董事，并于2017年6月成为我们的执行主席。Baxter先生自2005年以来一直是一名独立的公司财务顾问，主要为中间市场公司和密切持有的业务。此前，从2003年到2005年，他曾担任Diaz&Altschul Capital Management公司的董事总经理兼对冲基金销售与市场营销主管，在那里他的主要工作重点是将其投资产品带给潜在的公司和机构客户。他也曾是投资委员会成员。加入Diaz&Altschul公司之前，他曾担任SG Cowen Securities Corporation（法国银行的美国投资银行，SOCI T G N RALE）的董事总经理兼通才/跨国并购主管（从2000年到2002年）。在那里，他重新建立了跨境努力，并在全球范围内从事食品、零售、消费品、运输和石油天然气等行业。他也曾担任SG Cowen公平意见审查委员会的成员。任职SG Cowen公司之前，他曾任职Rothschild公司近6年（从1994年到2000年），在那里他专注于为工业/工程公司提供建议，包括汽车、国内和跨国并购、收购和资产剥离。他也曾担任SW Capital公司（并购精品店，专门从事财富500强公司的中间市场交易）的创始成员。在此之前，他是欧文信托公司企业财务咨询部的Vice President，为银行的客户提供并购和其他企业财务建议。他是Turning PointBrands，Inc.的董事纽约证券交易所代码:TPB（“转折点”），其他烟草产品的领先提供商。Baxter先生拥有加拿大维多利亚大学（University of Victoria）的工商管理学士学位和伦敦艾维商学院（Ivey Business School）的工商管理硕士学位。
- Gregory H. A Baxter joined the Company as a director in October 2015 and became our Executive Chairman in June 2017. Mr. Baxter has been an independent corporate finance consultant primarily for middle-market corporations and closely held businesses since 2005. Previously from 2003 to 2005 he was Managing Director and Head, Hedge Fund Sales and Marketing at Diaz & Altschul Capital Management, where his primary focus was bringing its investment products to prospective corporate and institutional clients. He was also a member of the Investment Committee. Immediately prior to joining Diaz & Altschul, he was Managing Director and Head of Generalist/Cross-Border Mergers & Acquisitions at SG Cowen Securities Corporation, the U.S. investment bank of French bank, Société Générale from 2000 to 2002. There, he re-established the cross-border effort and worked globally in industries such as food, retail, consumer products, transportation and oil and gas. He was also a member of the SG Cowen Fairness Opinion Review Committee. Prior to SG Cowen he was at Rothschild Inc. for almost six years, from 1994 to 2000 where he specialized in advising on industrial/engineering companies, including automotive, domestic and cross border mergers, acquisitions and divestitures. He was also a founding member of SW Capital, an M&A boutique that specialized in middle-market transactions for Fortune 500 companies. Prior to that, he was a Vice President of Irving Trust Company's Corporate Financial Counseling Department, providing M&A and other corporate finance advice to the bank's clients. He sits on the board of Turning Point Brands, Inc. NYSE: TPB ("Turning Point"), a leading provider of Other Tobacco Products. Mr. Baxter holds a holds a B.A. from the University of Victoria in Canada and an M.B.A. from the Ivey Business School in London.
- Ian Estus
Ian Estus于2016年8月加入公司担任董事，并于2017年6月成为公司总裁兼首席执行官。2014年5月至2016年7月，Estus先生担任HC2控股公司投资董事总经理纽交所股票代码:HCHC，一家多元化控股公司，投资于包括制造业、海洋服务、保险、公用事业、电信和生命科学在内的多个行业。在加入HC2之前，Estus先生是哈宾格投资集团有限公司子公司Five Island Asset Management的高级副总裁。NYSE:HRG，2013年4月至2014年5月。加入Five Island之前，他曾任职Harbinger Capital Partners LLC11年，在那里他曾担任多种职务，在那里他曾担任交易员，并协助管理投资组合。在2002年加入Harbinger Capital之前，Estus先生是Smith Barney Asset Management高收益投资集团的交易助理。在担任该职位之前，Estus先生曾担任Smith Barney Asset Management共同基金会计集团的基金会计。
Ian Estus joined the Company as a director in August 2016 and became our President and Chief Executive Officer in June 2017. From May 2014 until July 2016 Mr. Estus was the Managing Director of Investments of HC2 Holdings, Inc. NYSE: HCHC, a diversified holding company with investments in various industries including manufacturing, marine services, insurance, utilities, telecommunications and life sciences. Prior to joining HC2 Mr. Estus was a Senior Vice President at Five Island Asset Management, a subsidiary of HRG Group, Inc. NYSE: HRG, from April 2013 to May 2014. Prior to joining Five Island, Mr. Estus spent eleven years at Harbinger Capital Partners LLC, where he served in various capacities as a trader and assisting in management of the portfolio. Prior to joining Harbinger Capital in 2002 Mr. Estus was a Trading Assistant in the Smith Barney Asset Management High Yield Investments Group. Prior to that role, Mr. Estus served as a Fund Accountant in the Mutual Fund Accounting Group of Smith Barney Asset Management.- Ian Estus于2016年8月加入公司担任董事，并于2017年6月成为公司总裁兼首席执行官。2014年5月至2016年7月，Estus先生担任HC2控股公司投资董事总经理纽交所股票代码:HCHC，一家多元化控股公司，投资于包括制造业、海洋服务、保险、公用事业、电信和生命科学在内的多个行业。在加入HC2之前，Estus先生是哈宾格投资集团有限公司子公司Five Island Asset Management的高级副总裁。NYSE:HRG，2013年4月至2014年5月。加入Five Island之前，他曾任职Harbinger Capital Partners LLC11年，在那里他曾担任多种职务，在那里他曾担任交易员，并协助管理投资组合。在2002年加入Harbinger Capital之前，Estus先生是Smith Barney Asset Management高收益投资集团的交易助理。在担任该职位之前，Estus先生曾担任Smith Barney Asset Management共同基金会计集团的基金会计。
- Ian Estus joined the Company as a director in August 2016 and became our President and Chief Executive Officer in June 2017. From May 2014 until July 2016 Mr. Estus was the Managing Director of Investments of HC2 Holdings, Inc. NYSE: HCHC, a diversified holding company with investments in various industries including manufacturing, marine services, insurance, utilities, telecommunications and life sciences. Prior to joining HC2 Mr. Estus was a Senior Vice President at Five Island Asset Management, a subsidiary of HRG Group, Inc. NYSE: HRG, from April 2013 to May 2014. Prior to joining Five Island, Mr. Estus spent eleven years at Harbinger Capital Partners LLC, where he served in various capacities as a trader and assisting in management of the portfolio. Prior to joining Harbinger Capital in 2002 Mr. Estus was a Trading Assistant in the Smith Barney Asset Management High Yield Investments Group. Prior to that role, Mr. Estus served as a Fund Accountant in the Mutual Fund Accounting Group of Smith Barney Asset Management.
- Edward J. Sweeney
EdwardJ.Sweeney自2011年起担任董事总经理，临时担任公司首席财务官，自公司前首席财务官于2017年5月31日离职起生效。Sweeney先生作为众多客户的注册人和顾问，在证券交易委员会（SEC）的文件和法规方面有着丰富的经验，从公开发行、注册声明、中期和年度财务报告以及SEC意见书的解决，协助他们完成SEC合规的所有阶段。在加入Pine Hill Group之前，Sweeney先生曾在Endo Pharmaceuticals Inc.担任各种职务，最近的职务是2004年至2011年担任Vice President、财务总监和首席会计官，1991年至2004年担任安永会计师事务所审计高级经理等各种职务。Sweeney先生是一名注册会计师，并持有Saint Joseph’；s University会计学学士学位。
Edward J. Sweeney has served as Managing Director since 2011 to serve on an interim basis as the Company’s Chief Financial Officer, effective upon the departure of the Company’s former Chief Financial Officer on May 31 2017. Mr. Sweeney has significant experience with Securities and Exchange Commission “SEC” filings and regulations, as both a registrant and an advisor for numerous clients, assisting them through all phases of SEC compliance from public offerings, registration statements, interim and annual financial reporting and SEC comment letter resolution. Prior to joining Pine Hill Group, Mr. Sweeney served in varying capacities at Endo Pharmaceuticals Inc., most recently as Vice President, Controller and Chief Accounting Officer, from 2004 to 2011 and in various capacities, including Audit Senior Manager, at Ernst & Young LLP from 1991 to 2004. Mr. Sweeney is a Certified Public Accountant and holds a B.S. in Accounting from Saint Joseph’s University.- EdwardJ.Sweeney自2011年起担任董事总经理，临时担任公司首席财务官，自公司前首席财务官于2017年5月31日离职起生效。Sweeney先生作为众多客户的注册人和顾问，在证券交易委员会（SEC）的文件和法规方面有着丰富的经验，从公开发行、注册声明、中期和年度财务报告以及SEC意见书的解决，协助他们完成SEC合规的所有阶段。在加入Pine Hill Group之前，Sweeney先生曾在Endo Pharmaceuticals Inc.担任各种职务，最近的职务是2004年至2011年担任Vice President、财务总监和首席会计官，1991年至2004年担任安永会计师事务所审计高级经理等各种职务。Sweeney先生是一名注册会计师，并持有Saint Joseph’；s University会计学学士学位。
- Edward J. Sweeney has served as Managing Director since 2011 to serve on an interim basis as the Company’s Chief Financial Officer, effective upon the departure of the Company’s former Chief Financial Officer on May 31 2017. Mr. Sweeney has significant experience with Securities and Exchange Commission “SEC” filings and regulations, as both a registrant and an advisor for numerous clients, assisting them through all phases of SEC compliance from public offerings, registration statements, interim and annual financial reporting and SEC comment letter resolution. Prior to joining Pine Hill Group, Mr. Sweeney served in varying capacities at Endo Pharmaceuticals Inc., most recently as Vice President, Controller and Chief Accounting Officer, from 2004 to 2011 and in various capacities, including Audit Senior Manager, at Ernst & Young LLP from 1991 to 2004. Mr. Sweeney is a Certified Public Accountant and holds a B.S. in Accounting from Saint Joseph’s University.
- Bradford A. Tobin
BradfordA.Tobin于2018年1月16日加入公司，担任秘书and General Counsel。Tobin先生拥有超过10年的法律和运营经验。在加入该公司之前，Tobin先生曾担任General Wireless Operations Inc.DBA RadioShack的总法律顾问兼高级副总裁。在担任该职位之前，Tobin先生曾在Silver Point Capital，LP的不良债务团队任职。Tobin先生拥有纽约圣约翰大学法学院（St.John’；s University）的法学博士学位和威斯康星大学麦迪逊分校（University of Wisconsin-Madison）的经济学学士学位。
Bradford A. Tobin joined the Company as Secretary and General Counsel effective of January 16 2018. Mr. Tobin has over 10 years of legal and operational experience. Immediately prior to joining the Company, Mr. Tobin served as the General Counsel and Senior Vice President of General Wireless Operations Inc. dba RadioShack. Preceding this role, Mr. Tobin served on the distressed debt team at Silver Point Capital, LP. Mr. Tobin holds a Juris Doctor from St. John’s University, School of Law in New York and a B.S. in Economics from the University of Wisconsin-Madison.- BradfordA.Tobin于2018年1月16日加入公司，担任秘书and General Counsel。Tobin先生拥有超过10年的法律和运营经验。在加入该公司之前，Tobin先生曾担任General Wireless Operations Inc.DBA RadioShack的总法律顾问兼高级副总裁。在担任该职位之前，Tobin先生曾在Silver Point Capital，LP的不良债务团队任职。Tobin先生拥有纽约圣约翰大学法学院（St.John’；s University）的法学博士学位和威斯康星大学麦迪逊分校（University of Wisconsin-Madison）的经济学学士学位。
- Bradford A. Tobin joined the Company as Secretary and General Counsel effective of January 16 2018. Mr. Tobin has over 10 years of legal and operational experience. Immediately prior to joining the Company, Mr. Tobin served as the General Counsel and Senior Vice President of General Wireless Operations Inc. dba RadioShack. Preceding this role, Mr. Tobin served on the distressed debt team at Silver Point Capital, LP. Mr. Tobin holds a Juris Doctor from St. John’s University, School of Law in New York and a B.S. in Economics from the University of Wisconsin-Madison.